(Q38404608)

English

A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors

scientific article published on 21 March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors (English)

1 reference

Europe PubMed Central

2 September 2017

1 reference

based on heuristic

inferred from title

Leonard B. Saltz

9

1 reference

Europe PubMed Central

2 September 2017

author name string

Diane L Reidy-Lagunes

1

1 reference

Europe PubMed Central

2 September 2017

Efsevia Vakiani

2

1 reference

Europe PubMed Central

2 September 2017

Michal F Segal

3

1 reference

Europe PubMed Central

2 September 2017

Ellen M Hollywood

4

1 reference

Europe PubMed Central

2 September 2017

Laura H Tang

5

1 reference

Europe PubMed Central

2 September 2017

David B Solit

6

1 reference

Europe PubMed Central

2 September 2017

M Catherine Pietanza

7

1 reference

Europe PubMed Central

2 September 2017

Marinela Capanu

8

1 reference

Europe PubMed Central

2 September 2017

language of work or name

0 references

publication date

21 March 2012

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

118

1 reference

Europe PubMed Central

2 September 2017

19

1 reference

Europe PubMed Central

2 September 2017

4795-4800

1 reference

Europe PubMed Central

2 September 2017

Structure and function of the type 1 insulin-like growth factor receptor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

The role of the IGF system in cancer: from basic to clinical studies and clinical applications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

Insulin-like growth factors and neoplasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

mTOR signalling in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

Insulin-like growth factor-1 increases intracellular calcium concentration in human primary neuroendocrine pancreatic tumor cells and a pancreatic neuroendocrine tumor cell line (BON-1) via R-type Ca2+ channels and regulates chromogranin a secretion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

Genomic and biological characterization of exon 4 KRAS mutations in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

High-throughput oncogene mutation profiling in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

21 January 2018

Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27459

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27459

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38404608&oldid=1757831507"